The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes patients ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...